Amycretin Side Effects: Safety Signals and Warnings
Amycretin safety concerns are compound-specific. The main listed side effects are Nausea (most common), Vomiting, and Diarrhea. The main warning signals are Investigational agent - not yet approved for clinical use, Long-term safety and efficacy data not yet available, and GI side effects may limit tolerability at higher doses.
Direct Answer
Zenagamtide now has published Phase 2 evidence for both oral and weekly subcutaneous formulations, making it one of the better-documented next-generation obesity candidates. Phase 3 development is underway, but no Phase 3 outcome data or regulatory approval exists, so approved semaglutide and tirzepatide remain ahead on decision-grade evidence.
- Evidence grade
- Level B
- Research status
- Phase 3
- Category
- Weight Loss & Metabolic
- Evidence context
- Weight loss research, oral GLP-1/amylin dual agonism pharmacology, obesity treatment development
Reported Side Effects
- Nausea (most common)
- Vomiting
- Diarrhea
- Decreased appetite
- Constipation
Warnings
- Investigational agent - not yet approved for clinical use
- Long-term safety and efficacy data not yet available
- GI side effects may limit tolerability at higher doses
- Potential pancreatitis risk (class effect of GLP-1 agonists)
- Thyroid C-cell tumor risk unknown (class concern for GLP-1 agonists in rodents)
Known or Plausible Interactions
- Oral medications (delayed gastric emptying may affect absorption)
- Insulin and sulfonylureas (additive hypoglycemia risk)
- Other GLP-1 receptor agonists (not intended for combination use)
Regulatory Context
Investigational new drug. Novo Nordisk has advanced zenagamtide/amycretin into Phase 3 development for weight management in 2026; it is not approved by any regulatory authority and is not available outside clinical trials.
Evidence Snapshot
| Evidence grade | Level B |
|---|---|
| Research status | Phase 3 |
| Best supported outcomes | Body Weight Reduction (Level B), Glycemic Control (Level B), Appetite Suppression (Level B), and Gastrointestinal Tolerability (Level B) |
| Primary citation count | 4 |
| Last reviewed | 2026-08-27 |
Quick Answers
What are the side effects of Amycretin?
Amycretin safety concerns are compound-specific. The main listed side effects are Nausea (most common), Vomiting, and Diarrhea. The main warning signals are Investigational agent - not yet approved for clinical use, Long-term safety and efficacy data not yet available, and GI side effects may limit tolerability at higher doses.
What is the evidence level for Amycretin?
Amycretin is rated Level B. Its current research status is Phase 3.
What is Amycretin best known for?
Weight loss research, oral GLP-1/amylin dual agonism pharmacology, obesity treatment development.
Where can I read the full Amycretin evidence review?
The full evidence review is available at https://examinepeptides.com/library/amycretin.
Related Guides
How to Cite This Page
ExaminePeptides. "Amycretin Side Effects: Safety Signals and Warnings." Last reviewed 2026-08-27. https://examinepeptides.com/answers/amycretin-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.